# Phase III Trial of Sirolimus in IBM

> **NCT04789070** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 140 (estimated)

## Conditions studied

- Inclusion Body Myositis

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04789070
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04789070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04789070, "Phase III Trial of Sirolimus in IBM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04789070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*